Aneros Releases Eupho Syn Prostate Massager
HOUSTON — Aneros announces the newest addition to its line of signature prostate stimulators, Eupho Syn, shipping to retailers April 8.
The sleek design adds a silicone sleeve to the original Eupho Classic, with the synergy between the two materials adding a resilient give to the solid inner core. The familiar perianal stimulator ball and handle are replicated in the new design.
To download Eupho Syn promotional materials, visit http://www.aneros.com/media/#eupho_syn.
"The synergy between the softer silicone and the resilient core leads to amazing sensations," Aneros CEO CT Schenk said. “Eupho is a popular classic, with thousands of happy users, and Eupho Syn expands upon the tradition, making for a great addition to our collection of prostate massagers.”
Eupho Syn features a slim design and small head allowing for more targeted massages. Increased comfort is derived from the addition of a thick silicone coating over the rigid frame. According to the company, the Eupho Syn is ideal for men with stronger sphincter muscles, who can control the massaging capabilities through varied contractions.
“Using an Aneros prostate stimulator, a man can achieve strong, continuous full-body orgasms previously unattainable through conventional sexual techniques,” the company said. “Through practice, a man can have these orgasms one after the other during sessions lasting for an hour or more at a time.
“Aneros products can also be used during traditional sexual encounters. His prostate will empty more fully during ejaculation, which means a more intense and satisfying orgasm. Using an Aneros stimulator is an effective way for a man to explore and expand intimacy with his partner.”
In 2012, Aneros released the first Syn variation of one of its massagers — Helix Syn. The silicone enhanced prostate massager was acclaimed as Aneros’ bestselling product of the year. In addition to the phenomenal consumer response, Helix Syn was also named Male Pleasure Product of the Year at the 2013 XBIZ Awards. The company says initial interest and demand for Eupho Syn indicates similar results.